ライフサイエンスコーパス: infantile hemangioma

1 ram per day for 6 months in the treatment of infantile hemangioma.

2 clinical evaluation and treatment of CMN and infantile hemangioma.

3 guide future standard-of-care treatment for infantile hemangioma.

4 ng from systemic use of propranolol to treat infantile hemangioma.

5 lockers have been used to successfully treat infantile hemangioma.

6 c potential of stem cells derived from human infantile hemangioma.

7 -1 and merosin, immunodiagnostic markers for infantile hemangioma.

8 ar malformations, juvenile angiofibromas and infantile hemangiomas.

9 treatment of benign vascular tumors such as infantile hemangiomas.

10 romise for the treatment of certain types of infantile hemangiomas.

11 ine therapy for the treatment of complicated infantile hemangiomas.

12 fantile hemangiomas and treating complicated infantile hemangiomas.

13 sm of action of propranolol on regression of infantile hemangiomas.

14 nsible for the formation and rapid growth of infantile hemangiomas.

15 Objectives: To describe the sequelae left by infantile hemangiomas after natural involution and to id

16 opranolol has been used to treat complicated infantile hemangiomas, although data from randomized, co

17 tifies a stem cell as the cellular origin of infantile hemangioma and describes for what we believe i

18 s in a previously described in vivo model of infantile hemangioma and in cultured hemangioma-derived

19 es of these lesions are shared with those of infantile hemangioma and tufted angioma of children, but

20 is and psoriasis, use of topical timolol for infantile hemangiomas and bone marrow transplantation fo

21 e treatment of atopic dermatitis, psoriasis, infantile hemangiomas and dystrophic epidermolysis bullo

22 treatments for atopic dermatitis, psoriasis, infantile hemangiomas and dystrophic epidermolysis bullo

23 escribing clinical syndromes associated with infantile hemangiomas and treating complicated infantile

24 as wet age-related macular degeneration and infantile hemangioma are more common in light-skinned in

25 hat the transcriptomes of human placenta and infantile hemangioma are sufficiently similar to suggest

26 Infantile hemangiomas are benign tumors of vascular endo

27 Infantile hemangiomas are characterized by rapid capilla

28 Congenital melanocytic nevi (CMN) and infantile hemangiomas are commonly encountered in newbor

29 Infantile hemangiomas are composed of endothelial cells

30 Infantile hemangiomas are endothelial tumors that grow r

31 Infantile hemangiomas are localized and rapidly growing

32 As infantile hemangiomas are reported to express high level

33 Infantile hemangiomas are the most common benign tumors

34 Corticosteroids are commonly used to treat infantile hemangioma, but the mechanism of action of thi

35 ccurred in redefining the clinical course of infantile hemangiomas, describing clinical syndromes ass

36 Little is known about the pathogenesis of infantile hemangiomas despite the fact that they are rel

37 Although most CMN and infantile hemangiomas do not require active intervention

38 (3 mg/kg/day) in the treatment of periocular infantile hemangioma (IH) based on clinical and radiolog

39 Infantile hemangioma (IH) is a common childhood vascular

40 Infantile hemangioma (IH) is the most common tumor of in

41 Herein, we used infantile hemangioma (IH), the most common tumor of infa

42 (HemSCs) are multipotent cells isolated from infantile hemangioma (IH), which form hemangioma-like le

43 Infantile hemangiomas (IH) are common tumors for which t

44 Propranolol therapy for infantile hemangiomas (IH) is now being used widely, and

45 Infantile hemangiomas (IHs) are common benign tumors of

46 nign vascular tumors that differ from common infantile hemangiomas in that they grow in utero and are

47 Conventional treatments for infantile hemangioma include the use of corticosteroids,

48 Importance: Infantile hemangiomas involute to some extent, but they

49 Infantile hemangioma is a benign endothelial tumor compo

50 Infantile hemangioma is a common vascular tumor with a u

51 Infantile hemangioma is an endothelial tumor that grows

52 f the pathogenic endothelial cells in common infantile hemangioma is unknown.

53 evolutionized the treatment of proliferating infantile hemangiomas, laser and/or surgical excision ar

54 common, predominantly benign complication in infantile hemangioma, little is known about the prognosi

55 gests that the unique self-limited growth of infantile hemangioma may, in fact, mirror the lifetime o

56 e pathogenic C482R VEGFR-2 mutant, linked to infantile hemangioma, promotes ligand-independent signal

57 220 parents/caregivers completed the 35-item Infantile Hemangioma Quality-of-Life (IH-QoL) instrument

58 hat EndMT induced by M1 macrophages promotes infantile hemangioma regression and may lead to novel th

59 ants 1 to 5 months of age with proliferating infantile hemangioma requiring systemic therapy.

60 Human placenta and infantile hemangioma samples highly express ECSCR protei

61 etrospective cohort study of images from 187 infantile hemangiomas that had not received systemic tre

62 Most are benign infantile hemangiomas that typically regress by 5 years

63 he ECs of mature human placental vessels and infantile hemangiomas, the most common tumor of infancy

64 cells recapitulated the unique evolution of infantile hemangioma--the formation of blood vessels fol

65 udies have shown a promising new therapy for infantile hemangioma using nonselective beta-blockers, i